Loss of manufacturing capability as a result of regulatory non-compliance can have a devastating impact on biopharma or medical device manufacturers. In this article, Jenny Yu shares real-life examples from the industry and highlights the downstream effects of these business interruptions.
List view / Grid view
Filter the results
A new report has shown that from 2016/17 to 2018/19 clinical research has generated an estimated £8 billion of GVA for the UK.
The global biobetters market is set to increase due to demand for higher efficacy and safer drugs.
More ambitious changes may be needed to lower pharmaceutical prices as the Trump administration proposes new rules and approves a slew of new generic drugs.
Medical marketing increased substantially from 1997 through 2016, especially direct-to-consumer advertising for drugs and health services…
Corporate codes of ethics can have reverse effects and mask anomalies or social evils in operations outsourced to low-wage countries...
Wenzel Novak PhD gives some considerations on container, environment, process and automation for small batch sizes in the downstream process of fill-finish…
Valeant Pharmaceuticals has entered into an agreement to sell its iNova Pharmaceuticals business for $930 million in cash.
Health leaders announced the launch of the Alliance for Transparent & Affordable Prescriptions (ATAP), a coalition of provider and patient groups concerned about the practices of pharmacy benefit managers (PBMs) driving up drug costs.
Successful business year 2014: Sartorius achieves sales and earnings targets – positive outlook for 2015
Sartorius, a leading international laboratory and pharmaceutical equipment supplier, successfully closed fiscal 2014 according to its preliminary figures, and even slightly exceeded its sales revenue and earnings targets. In addition, the Group is set to further sharpen its strategic profile based on the sale of its smallest division, Industrial Technologies,…
Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the fourth quarter and full year of 2014, which were highlighted by strong global sales for priority brands and important advances in the company’s immuno-oncology (I-O) portfolio.